[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637995":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":15,"responsibleParty":35,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":18,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Insel Gruppe AG, University Hospital Bern","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Septic shock",null,"Patients in ICU with diagnosed septic shock",{"label":13,"type":10,"description":14,"interventionNames":10},"Critically ill patients","Critically ill patients in ICU without sepsis diagnosis",[16],{"facility":17,"status":18,"city":19,"state":10,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Inselspital","RECRUITING","Bern","3010","Switzerland","CH",{"type":24,"coordinates":25},"Point",[26,27],7.44744,46.94809,{"lat":27,"lon":26},[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Joerg C Schefold, Prof. Dr. med","CONTACT","0041 31 632 39 16","joerg.schefold@insel.ch",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100637995","mirna-quantification-in-patients-with-septic-shock-100637995",false,"NCT07597122","MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK","MIRSEP - MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK","MIRSEP","Inclusion Criteria:\n\nSeptic shock:\n\n* New onset (\\\u003C24h) of septic shock diagnosis according to Sepsis-3 definition\n* (suspected) infection\n* Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)\n* Serum lactate level \\> 2mmol\u002FL\n* Minimum age of 18 years\n* Expected length of stay \\>48h\n* Written consent from an independent physician\n\nCritically ill:\n\n* Patients on mechanical ventilation (MV) in the ICU without an admission diagnosis of sepsis\u002Fseptic shock according to Sepsis-3 definition\n* Minimum age of 18 years\n* Expected length of stay \\>48h\n* Written consent from an independent physician\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients known not to speak German or French\n* Patients with known.\n\n  1. Pre-existing congenital or acquired severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS) or\n  2. current immunosuppressive therapy (immunosuppressive biologicals or active lymphocyte therapy e.g. endoxan, rituximab or corticosteroid use at a dose \\> 10 mg\u002Fday equivalent of prednisone. However, acute corticosteroid treatment of a relative adrenal insufficiency using a maximum hydrocortisone dose of 200 mg\u002Fday is accepted.","ALL","18 Years",{"count":48,"type":49},56,"ESTIMATED","OBSERVATIONAL","Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.",[53],"Sepsis and Septic Shock",[9,55,56,57,58],"Sepsis induced immunusuppression","HLA-DR","miRNA","Monocytes","2026-06-01",{"date":61,"type":62},"2026-06-02","ACTUAL",{"date":59,"type":62},{"date":65,"type":49},"2027-12-31",{"name":5,"class":6},1]